October 17, 2025

Supplementary Figure 5 from Concordance between Tumor Tissue and Plasma DNA Genotyping in the NCI-MATCH Trial (EAY131)

Key Points

Genomic alterations were revealed in the tumor tissue and plasma DNA of HER2+ patients, influencing treatment decisions.
The analysis utilized stratification based on the best overall response to treatment with ado-trastuzumab emtansine.
Plasma DNA genotyping provided complementary information to tumor tissue analysis, enhancing the understanding of treatment efficacy.
Understanding the concordance of tumor tissue and plasma DNA can guide more personalized therapeutic strategies for cancer patients.

Abstract

Supplementary Figure 5. Genomic alterations detected in patients treated in subprotocol Q enrolling patients with HER2 amplifications who received treatment with ado-trastuzumab emtansine. Patients are stratified according to the best overall response. Triangles are used to depict the presence of mutation in tissue (lower triangle) and/or plasma (upper triangle).

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Cite this study

Gouda et al. (Wed,) studied this question.

www.synapsesocial.com/papers/68f199bfde32064e504dcaa7 — DOI: https://doi.org/10.1158/1078-0432.30363474

Authors

Mohamed A. Gouda

Filip Janků

Ying Yuan

Actions

References and Citations

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Supplementary Figure 5 from Concordance between Tumor Tissue and Plasma DNA Genotyping in the NCI-MATCH Trial (EAY131)

Key Points

Abstract

Citation Network

Connected Papers

Discussion

Cite this study

Authors

Actions

References and Citations

Citation Network

Connected Papers

Discussion